|
Markt geschlossen -
Andere Börsenplätze
|
Nachbörslich 21:59:58 | |||
| 80.29 EUR | -0.09% |
|
80.52 | +0.29% |
| 16:20 | Entera Bio Ltd. kündigt Veränderungen im Vorstand an | CI |
| 09:51 | Sanofi erhält FDA-Breakthrough-Therapy-Status für Anämie-Behandlung | MT |
Hauptkonkurrenten
| Umsatz (Y-1) | Nettogewinn (Y-1) | EBIT-Marge (Y-1) | ROE (Y-1) | ROA (Y-1) | Verschuldungsgrad (Y-1) | ||
|---|---|---|---|---|---|---|---|
| 42.53 Mrd. | 13.98% | 27.61% | 11.75% | 4.43% | 0.68x | ||
| 45.04 Mrd. | 23.51% | 31.78% | 84.84% | 14.84% | 1.88x | ||
| 88.82 Mrd. | 15.84% | 29.8% | 34.23% | 13.95% | 0.41x | ||
| 56.33 Mrd. | 7.59% | 41.43% | 263.08% | 13.34% | 2.56x | ||
| 77.58 Mrd. | 20.94% | 35.49% | 44.26% | 13.87% | 0.62x | ||
| 64.17 Mrd. | 26.68% | 36.46% | 46.35% | 17.38% | 0.86x | ||
| 54.07 Mrd. | 13.01% | 31.31% | 32.11% | 12.51% | 1.47x | ||
| 56.67 Mrd. | 24.64% | 38.62% | 38.4% | 16.33% | 1.02x | ||
| 48.59 Mrd. | 33.14% | 41.3% | 60.7% | 20.31% | 0.69x | ||
| 33.42 Mrd. | 12.24% | 44.96% | 177.29% | 11.36% | 2.33x | ||
| 28.75 Mrd. | 1.67% | 29.63% | 27.6% | 9.57% | 1.48x | ||
| 63.63 Mrd. | 12.62% | 34.24% | 19.99% | 8.05% | 1.52x | ||
| 48.3 Mrd. | -18.53% | 10.77% | 10.23% | -9.53% | 6.49x | ||
| 11.02 Mrd. | -4.86% | 6.31% | 0.65% | 0.49% | -6.77x | ||
| 39.28 Mrd. | 8.21% | 29.16% | 48.09% | 10.97% | 1.22x | ||
| 7.45 Mrd. | 33.09% | 46.3% | 22% | 18.71% | -1.74x | ||
| 30.6 Mrd. | 2.36% | 7.48% | 1.5% | 1.19% | 3.6x | ||
| 3.83 Mrd. | 22.64% | 26.77% | 14.73% | 13.49% | -2.98x | ||
| 48.25 Mrd. | -5.48% | 11.66% | 15.32% | -2.25% | 3.2x | ||
| Durchschnitt | 44.65 Mrd. | 12.8% | 29.53% | 50.16% | 9.95% | 0.98x | |
| Gewichteter Durchschnitt nach Marktkapitalisierung | 53.76 Mrd. | 16.41% | 32.65% | 69.49% | 12.61% | 1.21x |
- Börse
- Aktien
- 920657 Aktie
- Sektor Sanofi
- Finanzielle Vergleiche
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
MarketScreener is also available in this country: United States.
Switch edition
Bei der aktuellen länderspezifischen Edition bleiben
















